Key facts
- It has raised $9.7M; the latest was Early Stage VC ($9.7M) in Jan 2026.
- Notable investors include Altos Ventures, Spring Camp, TAIL Ventures.
- Status: Privately Held (backing).
Investors
3- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Innoxus
- ·The full record, as it builds
Funding rounds
No funding rounds for Innoxus are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Innoxus
Developer of aesthetic medical devices designed to lift and tighten skin. The company's device reduces wrinkles around the eyes, cheekbone reduction, treats sagging cheeks, and facial line improvement, enabling people to delay the aging process.
- Sector
- Healthcare
- HQ
- Anyang, South Korea
- Founded
- 2022
- Website
- innoxus.co.kr/
- Ownership
- Privately Held (backing)
Innoxus doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Innoxus shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Innoxus in its N-PORT filings yet. We sweep new filings monthly.